Provided by Tiger Trade Technology Pte. Ltd.

Vincerx Pharma, Inc.

0.0126
0.0000
Volume:390.00
Turnover:4.94
Market Cap:65.95K
PE:0.00
High:0.0126
Open:0.0126
Low:0.0126
Close:0.0126
52wk High:1.22
52wk Low:0.0002
Shares:5.23M
Float Shares:4.94M
Volume Ratio:0.27
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9799
EPS(LYR):-15.8451
ROE:-3136.43%
ROA:-197.53%
PB:0.03
PE(LYR):0.00

Loading ...

BUZZ-Vincerx Pharma soars on QumulusAI merger deal

Reuters
·
Mar 18, 2025

Vincerx Pharma : as of Feb 28, 2025, Had About$3.9 Mln in Cash and Anticipates Its Cash Runway Will Extend Into Late Q2 2025

THOMSON REUTERS
·
Mar 18, 2025

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination With Qumulusai

THOMSON REUTERS
·
Mar 18, 2025

Vincerx Pharma Inc - Qumulusai Equity Holders to Own 95% of Combined Company

THOMSON REUTERS
·
Mar 18, 2025

Vincerx Pharma Inc - Qumulusai to Become Publicly Traded Through Reverse Triangular Merger

THOMSON REUTERS
·
Mar 18, 2025

Press Release: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

Dow Jones
·
Mar 18, 2025

Vincerx Pharma Terminates Reverse Merger Deal With Oqory

Dow Jones
·
Mar 01, 2025

BRIEF-Vincerx Pharma Announces Termination Of Reverse Merger Term Sheet

Reuters
·
Mar 01, 2025

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

THOMSON REUTERS
·
Mar 01, 2025

Vincerx Pharma Inc - Cash Runway Expected to Extend Through Late Q2 2025

THOMSON REUTERS
·
Mar 01, 2025

Press Release: Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

Dow Jones
·
Mar 01, 2025

BRIEF-Vincerx Pharma Regains Compliance With Nasdaq Listing Rule 5550(A)(2)

Reuters
·
Feb 19, 2025

Vincerx Pharma Inc - Regains Compliance With Nasdaq Listing Rule 5550(a)(2)

THOMSON REUTERS
·
Feb 19, 2025

Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's Trop2 Antibody Drug Conjugate, Oqy-3258

THOMSON REUTERS
·
Jan 29, 2025

Press Release: Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258

Dow Jones
·
Jan 29, 2025

BRIEF-Vincerx Pharma Inc Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing

Reuters
·
Jan 25, 2025